Averitas Pharma, Inc.
Quick facts
Marketed products
- Capsaicin 8% · Pain Management
Capsaicin activates TRPV1 nociceptors on nerve fibers, causing initial stimulation followed by desensitization and depletion of substance P, resulting in reduced pain signaling.
Phase 3 pipeline
- capsaicin 0.04% topical system
Capsaicin activates and then desensitizes TRPV1 receptors on sensory nerve endings, reducing pain signal transmission.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Averitas Pharma, Inc.
What are Averitas Pharma, Inc.'s marketed drugs?
Top marketed products include Capsaicin 8%.
What is Averitas Pharma, Inc.'s pipeline?
Averitas Pharma, Inc. has 1 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include capsaicin 0.04% topical system.
Related
- Capsaicin 8% · Pain Management
- Sector hub: All tracked pharma companies